Next Article in Journal
An Equivocal SCC Lesion—Antiepileptic-Induced CLOCC
Next Article in Special Issue
Assessing Anti-Social and Aggressive Behavior in a Zebrafish (Danio rerio) Model of Parkinson’s Disease Chronically Exposed to Rotenone
Previous Article in Journal
Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
Previous Article in Special Issue
Naturalistic Study of Depression Associated with Parkinson’s Disease in a National Public Neurological Referral Center in Mexico
 
 
Article

Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study

1
CHUAC (Complejo Hospitalario Universitario de A Coruña), 15006 A Coruña, Spain
2
Hospital San Rafael, 15009 A Coruña, Spain
3
CHUS (Complejo Hospitalario Universitario de Santiago), Santiago de Compostela, 15706 A Coruña, Spain
4
Memory Unit, Hospital Universitario Juan Ramón Jiménez, 21005 Huelva, Spain
5
Unidad de Trastornos del Movimiento, Servicio de Neurología, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria (ibs.Granada), 18013 Granada, Spain
6
Neurology Department, Puerta del Mar University Hospital, 11009 Cádiz, Spain
7
Complejo Público Asistencial de Zamora, 49022 Zamora, Spain
*
Author to whom correspondence should be addressed.
Academic Editors: Patricia Martinez-Sanchez and Francisco Nieto-Escamez
Brain Sci. 2022, 12(3), 383; https://doi.org/10.3390/brainsci12030383
Received: 16 February 2022 / Revised: 9 March 2022 / Accepted: 10 March 2022 / Published: 12 March 2022
Patients with Parkinson’s disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson’s Disease) is a prospective open-label single-arm study conducted in 5 centers from Spain. The primary efficacy outcome was the change from baseline (V0) to the end of the observational period (6 months ± 30 days) (V2) in the Non-Motor Symptoms Scale (NMSS) total score. Different scales were used for analyzing the change in motor, NMS, quality of life (QoL), and disability. Thirty-three patients were included between JUL/2019 and JUN/2021 (age 63.3 ± 7.91; 60.6% males; 7.48 ± 4.22 years from symptoms onset). At 6 months, 30 patients completed the follow-up (90.9%). The NMSS total score was reduced by 27.3% (from 71.67 ± 37.12 at V0 to 52.1 ± 34.76 at V2; Cohen’s effect size = −0.97; p = 0.002). By domains, improvement was observed in sleep/fatigue (−40.1%; p < 0.0001), mood/apathy (−46.6%; p = 0.001), gastrointestinal symptoms (−20.7%; p = 0.029), and miscellaneous (−44.94%; p = 0.021). QoL also improved with a 18.4% reduction in the 39-item Parkinson’s Disease Quality of Life Questionnaire Summary Index (from 26.67 ± 17.61 at V0 to 21.75 ± 14.9 at V2; p = 0.001). A total of 13 adverse events in 11 patients (33.3%) were reported, 1 of which was severe (not related to opicapone). Dyskinesias and nausea were the most frequent (6.1%). Opicapone is well tolerated and improves global NMS burden and QoL in PD patients at 6 months. View Full-Text
Keywords: effectiveness; non-motor symptoms; open-label study; opicapone; Parkinson’s disease effectiveness; non-motor symptoms; open-label study; opicapone; Parkinson’s disease
Show Figures

Figure 1

MDPI and ACS Style

Santos García, D.; Fernández Pajarín, G.; Oropesa-Ruiz, J.M.; Escamilla Sevilla, F.; Rahim López, R.R.A.; Muñoz Enríquez, J.G. Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study. Brain Sci. 2022, 12, 383. https://doi.org/10.3390/brainsci12030383

AMA Style

Santos García D, Fernández Pajarín G, Oropesa-Ruiz JM, Escamilla Sevilla F, Rahim López RRA, Muñoz Enríquez JG. Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study. Brain Sciences. 2022; 12(3):383. https://doi.org/10.3390/brainsci12030383

Chicago/Turabian Style

Santos García, Diego, Gustavo Fernández Pajarín, Juan Manuel Oropesa-Ruiz, Francisco Escamilla Sevilla, Raúl Rashid Abdul Rahim López, and José Guillermo Muñoz Enríquez. 2022. "Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study" Brain Sciences 12, no. 3: 383. https://doi.org/10.3390/brainsci12030383

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop